← All indications
Hidradenitis Suppurativa
A chronic suppurative and cicatricial disease of the apocrine glands occurring chiefly in the axillae in women and in the groin and anal regions in men. It is characterized by poral occlusion with secondary bacterial infection, evolving into abscesses which eventually rupture. As the disease becomes chronic, ulcers appear, sinus tracts enlarge, fistulas develop, and fibrosis and scarring become evident.
Drugs by status
Phase 4 trials (4)
Phase 3 trials (12)
Phase 2 trials (54)
- roflumilast
- brodalumab
- anifrolumab
- brensocatib
- apremilast
- cfz533
- cjm112
- tofacitinib
- etanercept
- gentian violet
- ethinyl estradiol
- guselkumab
- hydroxychloroquine
- ifx-1
- drospirenone
- ltx-109
- ly3041658
- ly3090106
- pf-06650833
- ritlecitinib
- Brepocitinib
- methylene blue
- fostamatinib
- risankizumab
- cannabis
- ustekinumab
- human fecal microbiota
- t2-18c3
- infliximab
- medi-8968
- +24 more
Phase 1 trials (11)
Organizations
Organization Involved with Phase 4 Indications (6)
Organization Involved with Phase 3 Indications (3)
Organization Involved with Phase 2 Indications (36)
- Incyte
- Abbott
- Celgene
- Bausch Health Companies
- AstraZeneca
- Eli Lilly
- Pfizer
- Bayer
- ChemoCentryx
- InflaRx GmbH
- XBiotech, Inc.
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- University of Pennsylvania
- University of Pittsburgh
- Florida Academic Dermatology Centers
- University of Groningen
- University of Athens
- University of Bern
- University of Zurich
- University of California, San Diego
- University of California, San Francisco
- University of Colorado, Denver
- Icahn School of Medicine at Mount Sinai
- Covance
- University of Amsterdam
- Hellenic Institute for the Study of Sepsis
- Dermatologisk Afdeling, Roskilde, Denmark
- Dessau Medical Center
- Dermato-verenologisk afdeling S, Denmark
- Ruhr University Bochum
- +6 more
Organization Involved with Phase 1 Indications (11)
Organization Involved with Other Experimental Indications (6)